MLTX - MoonLake Immunotherapeutics

17.22
-0.670   -3.891%

Share volume: 716,559
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$17.89
-0.67
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 24%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.11%
1 Month
2.07%
3 Months
10.24%
6 Months
79.38%
1 Year
-56.35%
2 Year
-58.02%
Key data
Stock price
$17.22
P/E Ratio 
0.00
DAY RANGE
$17.12 - $18.04
EPS 
-$3.16
52 WEEK RANGE
$5.95 - $62.75
52 WEEK CHANGE
-$56.42
MARKET CAP 
846.561 M
YIELD 
N/A
SHARES OUTSTANDING 
71.728 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$842,042
AVERAGE 30 VOLUME 
$1,292,382
Company detail
CEO: Jorge Santos da Silva
Region: US
Website: moonlaketx.com
Employees: 2
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, or ankylosing spondylitis.

Recent news